Polyceutix
About
Polyceutix' lead is a first-in-class cancer immunotherapy that lets the immune system see thousands of tumor-specific proteins at once instead of a few selected targets. This has translated into strong preclinical efficacy of our ready drug candidate.
We are further using our Native Nanodisc platform to generate novel targeted therapies for membrane protein related autoimmune diseases in neurology and cardiology.
What is your business/industry sector?
Biotech, Pharma and Cosmetics